Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals, a global leader in specialty pharmaceuticals, is headquartered in the United Kingdom. Founded in 1867, the company has established a strong presence in key operational regions, including North America and Europe. With a focus on pain management, autoimmune disorders, and critical care, Mallinckrodt is renowned for its innovative therapies and unique formulations. The company’s core products, such as specialty generics and branded medications, are designed to address complex medical needs, setting them apart in a competitive market. Notable achievements include a robust portfolio of FDA-approved treatments and a commitment to advancing patient care through research and development. As a trusted name in the pharmaceutical industry, Mallinckrodt continues to make significant strides in improving health outcomes worldwide.
DitchCarbon Score
How does Mallinckrodt Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mallinckrodt Pharmaceuticals's score of 41 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mallinckrodt Pharmaceuticals's reported carbon emissions
In 2023, Mallinckrodt Pharmaceuticals reported total carbon emissions of approximately 89,052,000 kg CO2e for Scope 1 and about 74,164,000 kg CO2e for Scope 2, resulting in a combined total of around 162,999,000 kg CO2e for both scopes. This reflects a slight decrease from 2022, where Scope 1 emissions were about 89,551,000 kg CO2e and Scope 2 emissions were approximately 82,347,000 kg CO2e, leading to a total of around 171,898,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by the middle of this decade (2025). Additionally, Mallinckrodt has committed to a 30% reduction in Scope 1 and Scope 2 emissions from a 2022 baseline by 2030. These targets demonstrate the company's proactive approach to addressing climate change and reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mallinckrodt Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
